Anneli Nordqvist completed her Ph.D. from Uppsala University (Sweden) where her work included organic synthesis, virtual screening and both ligand‒based and structure‒based drug design within the field of antituberculosis drug discovery. During the last year of her PhD she also worked as a consultant in computational chemistry at the CNS & Pain unit at AstraZeneca, Södertälje. Within CVMD Anneli has been working as a computational chemist in all phases of drug discovery from target selection to lead optimization and currently also works as lead chemist in a project in hit identification phase. Her research interests are focused around GPCR drug discovery, nuclear hormone receptors and the application of computational methods to facilitate drug discovery research.